{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:47:09Z","timestamp":1788839229777,"version":"build-2803163510"},"reference-count":171,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jceh.2026.103631","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T15:20:56Z","timestamp":1784992856000},"page":"103631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact"],"prefix":"10.1016","volume":"16","author":[{"given":"Patricia S.","family":"Castillo-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itzayana","family":"Rodr\u00edguez-Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misael","family":"Uribe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norberto C.","family":"Ch\u00e1vez-Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo E.","family":"Montalvo-Jav\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7616-2661","authenticated-orcid":false,"given":"Natalia","family":"Nu\u00f1o-L\u00e1mbarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2026.103631_bib1","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","article-title":"Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer","volume":"34","author":"Huang","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/medicina58020290","article-title":"Nash Up, virus Down: how the waiting list is changing for liver transplantation: a single center experience from Italy","volume":"58","author":"Ferrarese","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.jceh.2026.103631_bib5","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.13751","article-title":"Nonalcoholic fatty liver disease is an increasing indication for liver transplantation in the nordic countries","volume":"38","author":"Holmer","year":"2018","journal-title":"Liver Int"},{"issue":"suppl l","key":"10.1016\/j.jceh.2026.103631_bib6","first-page":"S32","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib7","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jceh.2022.07.179","article-title":"Patients with metabolic-dysfunction associated fatty liver disease (MAFLD) without associated etiologies and non-MAFLD non-alcoholic fatty liver disease (NAFLD) have similar liver disease severity - data from Indian consortium on NAFLD (ICON-D)","volume":"12","author":"Duseja","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib8","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3390\/nu5072708","article-title":"Obesity and dyslipidemia in South Asians","volume":"5","author":"Misra","year":"2013","journal-title":"Nutrients"},{"key":"10.1016\/j.jceh.2026.103631_bib9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cld.2015.10.002","article-title":"The metabolic syndrome and its influence on nonalcoholic steatohepatitis","volume":"20","author":"Kanwar","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2026.103631_bib10","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","article-title":"Changing epidemiology, global trends and implications for outcomes of NAFLD","volume":"79","author":"Wong","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41586-019-1171-x","article-title":"Rising rural body-mass index is the main driver of the global obesity epidemic in adults","volume":"569","author":"Bixby","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jceh.2026.103631_bib12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib13","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jceh.2021.11.010","article-title":"Prevalence of non-alcoholic fatty liver disease in India: a systematic review and meta-analysis","volume":"12","author":"Shalimar","year":"2021","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1464-5491.2005.01582.x","article-title":"Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults","volume":"22","author":"Jimba","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.jceh.2026.103631_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cld.1141","article-title":"Nonalcoholic fatty liver disease: indian perspective","volume":"18","author":"De","year":"2021","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jceh.2026.103631_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/s41366-023-01346-w","article-title":"Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD","volume":"47","author":"De","year":"2023","journal-title":"Int J Obes"},{"key":"10.1016\/j.jceh.2026.103631_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103631_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.12964","article-title":"Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study","volume":"286","author":"Park","year":"2019","journal-title":"J Intern Med"},{"key":"10.1016\/j.jceh.2026.103631_bib19","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jhep.2017.09.012","article-title":"Association between non-alcoholic fatty liver disease and cancer incidence rate","volume":"68","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib21","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib22","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jceh.2026.103631_bib23","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.cgh.2020.06.048","article-title":"Prevalence of liver steatosis and fibrosis detected by transient elastography in adolescents in the 2017\u20132018 national health and nutrition examination survey","volume":"19","author":"Ciardullo","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jceh.2026.103631_bib25","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/liv.14279","article-title":"Polycystic ovary syndrome (PCOS) is associated with NASH severity and advanced fibrosis","volume":"40","author":"Sarkar","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103631_bib26","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.3748\/wjg.v26.i20.2669","article-title":"Association between non-alcoholic fatty liver disease and obstructive sleep apnea","volume":"26","author":"Umbro","year":"2020","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bjd.16239","article-title":"Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?","volume":"179","author":"Prussick","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155270","article-title":"Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases","volume":"135","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2026.103631_bib29","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000828","article-title":"Metabolic dysfunction and alcohol-associated liver disease: a narrative review","volume":"16","author":"Dunn","year":"2025","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib30","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","article-title":"Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease","volume":"81","author":"Marti-Aguado","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib31","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jhep.2025.05.030","article-title":"Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification","volume":"83","author":"Tavaglione","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrendo.2015.189","article-title":"Regulation of metabolism by the innate immune system","volume":"12","author":"Lackey","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jceh.2026.103631_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jceh.2026.103631_bib34","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/hep.29689","article-title":"New insights into the role and mechanism of c-jun-n-terminal kinase signaling in the pathobiology of liver diseases","volume":"67","author":"Win","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib35","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1126\/science.1104343","article-title":"Mitochondrial dysfunction and type 2 diabetes","volume":"307","author":"Lowell","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jceh.2026.103631_bib36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.jceh.2026.103631_bib37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jceh.2026.103631_bib38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3945\/an.113.004648","article-title":"Hepatic fatty acid trafficking: multiple forks in the road","volume":"4","author":"Mashek","year":"2013","journal-title":"Adv Nutr"},{"key":"10.1016\/j.jceh.2026.103631_bib39","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1210\/clinem\/dgae028","article-title":"Lipidomic analysis reveals alterations in hepatic FA profile associated with MASLD stage in patients with obesity","volume":"109","author":"N\u00fa\u00f1ez-S\u00e1nchez","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib40","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1572-0241.2003.07725.x","article-title":"Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-Octanoate breath test","volume":"98","author":"Miele","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107401","article-title":"The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease","volume":"203","author":"Song","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103631_bib42","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","article-title":"The interaction of hepatic lipid and glucose metabolism in liver diseases","volume":"56","author":"Bechmann","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib43","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.3748\/wjg.v16.i38.4773","article-title":"Hepatic steatosis, low-grade chronic inflammation and hormone\/growth factor\/adipokine imbalance","volume":"16","author":"Tarantino","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib44","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MEG.0b013e3283229b40","article-title":"Could inflammatory markers help diagnose nonalcoholic steatohepatitis?","volume":"21","author":"Tarantino","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1467-789X.2012.01035.x","article-title":"Visceral fat and metabolic inflammation: the portal theory revisited","volume":"13","author":"Item","year":"2012","journal-title":"Obesity Obesity Reviews"},{"key":"10.1016\/j.jceh.2026.103631_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007929","article-title":"IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis","volume":"4","author":"Mas","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2026.103631_bib47","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1053\/meta.2000.9523","article-title":"Change of cytokine balance in diet-induced obese mice","volume":"49","author":"Mito","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.jceh.2026.103631_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12865-017-0215-y","article-title":"The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice","volume":"18","author":"He","year":"2017","journal-title":"BMC Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib49","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1324052111","article-title":"Spleen supports a pool of innate-like B cells in white adipose tissue that protects against obesity-associated insulin resistance","volume":"111","author":"Wu","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jceh.2026.103631_bib50","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3390\/jcm8101510","article-title":"Is there a link between basal metabolic rate, spleen volume and hepatic growth factor levels in patients with obesity-related NAFLD?","volume":"8","author":"Tarantino","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jceh.2026.103631_bib51","first-page":"228","article-title":"Hepato-splenic axis: hepatic and splenic metabolic activities are linked","volume":"8","author":"Keramida","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jceh.2026.103631_bib52","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1186\/s13104-018-3862-z","article-title":"High-fat, high-sugar diet induces splenomegaly that is ameliorated with exercise and genistein treatment","volume":"11","author":"Buchan","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.jceh.2026.103631_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186423","article-title":"Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations","volume":"135","author":"Schnabl","year":"2025","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jceh.2026.103631_bib54","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/antiox13111386","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Scarpellini","year":"2024","journal-title":"Antioxidants"},{"key":"10.1016\/j.jceh.2026.103631_bib55","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2500099","article-title":"Advances in the acting mechanism and treatment of gut microbiota in metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Wu","year":"2025","journal-title":"Gut Microbes"},{"key":"10.1016\/j.jceh.2026.103631_bib56","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.14309\/ajg.0000000000000661","article-title":"Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial","volume":"115","author":"Craven","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-024-03356-y","article-title":"Efficacy of probiotics, prebiotics, and synbiotics on liver enzymes, lipid profiles, and inflammation in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Pan","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib58","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MEG.0000000000002719","article-title":"Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis","volume":"36","author":"Wongtrakul","year":"2024","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib59","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/db19-0138","article-title":"Glucolipotoxicity, \u03b2-Cells, and diabetes: the emperor has no clothes","volume":"69","author":"Weir","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.jceh.2026.103631_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib61","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1172\/JCI29103","article-title":"Islet beta cell failure in type 2 diabetes","volume":"116","author":"Prentki","year":"2006","journal-title":"J Clin Investig"},{"key":"10.1016\/j.jceh.2026.103631_bib62","doi-asserted-by":"crossref","first-page":"22227","DOI":"10.1074\/jbc.M111.228874","article-title":"Sirtuin 1 (SIRT1) protein degradation in response to persistent c-Jun N-terminal kinase 1 (JNK1) activation contributes to hepatic steatosis in obesity","volume":"286","author":"Gao","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jceh.2026.103631_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/diabetology6040023","article-title":"Metabolic-associated steatotic liver disease (MASLD) and type 2 diabetes: mechanisms, diagnostic approaches, and therapeutic interventions","volume":"6","author":"Ntikoudi","year":"2025","journal-title":"Diabetology"},{"key":"10.1016\/j.jceh.2026.103631_bib64","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103631_bib65","doi-asserted-by":"crossref","first-page":"440","DOI":"10.4093\/dmj.2023.0200","article-title":"Glycemic control is associated with histological findings of nonalcoholic fatty liver disease","volume":"48","author":"Miyake","year":"2024","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jceh.2026.103631_bib66","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103631_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70256","article-title":"Glucagon-like Peptide-1 receptor agonists improve MASH and liver fibrosis: a meta-analysis of randomised controlled trials","volume":"45","author":"Mantovani","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2026.103631_bib68","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3350\/cmh.2025.0825","article-title":"Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis","volume":"32","author":"Choi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib69","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2026.103631_bib70","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103631_bib71","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib72","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib73","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib74","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/dom.14484","article-title":"Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications","volume":"24","author":"Byrne","year":"2022","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jceh.2026.103631_bib75","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MEG.0000000000001075","article-title":"Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis","volume":"30","author":"Zhou","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib77","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"Dunn","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib78","doi-asserted-by":"crossref","DOI":"10.1186\/s12872-020-01444-x","article-title":"Higher fatty liver index is associated with increased risk of new onset heart failure in healthy adults: a nationwide population-based study in Korea","volume":"20","author":"Roh","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jceh.2026.103631_bib79","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2026.103631_bib80","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12020-019-02070-0","article-title":"Association between nonalcoholic fatty liver disease and cardiac function and structure\u2014a meta-analysis","volume":"66","author":"Borges-Canha","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.jceh.2026.103631_bib81","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacep.2020.05.023","article-title":"Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jceh.2026.103631_bib82","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2019.01.035","article-title":"The degree of hepatic steatosis associates with impaired cardiac and autonomic function","volume":"70","author":"Houghton","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib83","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.00551","article-title":"Dysregulated neurovascular control underlies declining microvascular functionality in people with non-alcoholic fatty liver disease (NAFLD) at risk of liver fibrosis","volume":"11","author":"Clough","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jceh.2026.103631_bib84","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/aacf12","article-title":"The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the 13C-ketoisocaproate breath test","volume":"12","author":"Afolabi","year":"2018","journal-title":"J Breath Res"},{"key":"10.1016\/j.jceh.2026.103631_bib85","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3748\/wjg.v23.i19.3396","article-title":"Renin angiotensin system in liver diseases: friend or foe?","volume":"23","author":"Silva","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jceh.2026.103631_bib86","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2021.04.003","article-title":"Pericardial fat and the risk of heart failure","volume":"77","author":"Kenchaiah","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jceh.2026.103631_bib87","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijcard.2018.01.046","article-title":"Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis","volume":"259","author":"Simon","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jceh.2026.103631_bib88","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/apt.15738","article-title":"Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis","volume":"51","author":"Carlsson","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103631_bib89","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention","volume":"42","author":"Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.jceh.2026.103631_bib90","doi-asserted-by":"crossref","unstructured":"Alicic, R.Z., Rooney, M.T., and Tuttle, K.R. Diabetic kidney disease. Clin J Am Soc Nephrol 12, 2032\u20132045.","DOI":"10.2215\/CJN.11491116"},{"key":"10.1016\/j.jceh.2026.103631_bib91","first-page":"2032","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"12","author":"Rich","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jceh.2026.103631_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101506","article-title":"Steatotic liver disease, MASLD and risk of chronic kidney disease","volume":"50","author":"Bilson","year":"2024","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib93","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.molmed.2015.08.005","article-title":"Emerging liver-kidney interactions in nonalcoholic fatty liver disease","volume":"21","author":"Musso","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jceh.2026.103631_bib94","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/ndt\/gfab176","article-title":"Role of non-alcoholic fatty liver disease in the evolution of renal function in patients with diabetes mellitus","volume":"37","author":"Aubert","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jceh.2026.103631_bib95","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030269","article-title":"Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease","volume":"12","author":"Miyamori","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jceh.2026.103631_bib96","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41581-021-00423-5","article-title":"Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations","volume":"17","author":"Noels","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.jceh.2026.103631_bib97","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1152\/ajpendo.00244.2022","article-title":"Fibroblast growth factor 21 as a potential master regulator in metabolic disorders","volume":"324","author":"Velingkar","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib98","series-title":"FGF21 and Chronic Kidney Disease. Metabolism","first-page":"118","author":"Salgado","year":"2021"},{"key":"10.1016\/j.jceh.2026.103631_bib99","first-page":"1","article-title":"Oxidative stress and inflammation in renal and cardiovascular complications of diabetes","volume":"10","author":"Charlton","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jceh.2026.103631_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113320","article-title":"Nonalcoholic fatty liver disease and chronic kidney disease: epidemiology, pathogenesis, and clinical and research implications","volume":"23","author":"Lonardo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jceh.2026.103631_bib101","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00179.2022","article-title":"Obesity and chronic kidney disease","volume":"324","author":"Jiang","year":"2023","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib102","first-page":"245","article-title":"PPAR-\u03b3 signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets","author":"Chen","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jceh.2026.103631_bib103","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/resp.13838","article-title":"Global burden of sleep-disordered breathing and its implications","volume":"25","author":"Lyons","year":"2020","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.jceh.2026.103631_bib104","first-page":"522","article-title":"A systematic review of oral myofunctional therapy for future treatment in pediatric obstructive sleep apnea (OSA)","volume":"11","author":"Achmad","year":"2020","journal-title":"Systematic Reviews in Pharmacy"},{"key":"10.1016\/j.jceh.2026.103631_bib105","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.13616","article-title":"Obstructive sleep apnea: transition from pathophysiology to an integrative disease model","volume":"31","author":"McNicholas","year":"2022","journal-title":"J Sleep Res"},{"key":"10.1016\/j.jceh.2026.103631_bib106","series-title":"Obstructive Sleep Apnoea Syndrome A Systematic Literature Review the Swedish Council on Technology Assessment in Health Care","year":"2007"},{"key":"10.1016\/j.jceh.2026.103631_bib107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107380","article-title":"Age-group-specific associations between the severity of obstructive sleep apnea and relevant risk factors in male and female patients","volume":"9","author":"Deng","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jceh.2026.103631_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-019-0258-7","article-title":"Insulin resistance mediates high-fat diet-induced pulmonary fibrosis and airway hyperresponsiveness through the TGF-\u03b21 pathway","volume":"51","author":"Park","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.jceh.2026.103631_bib109","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.hbpd.2018.01.007","article-title":"Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: either non-obese or obese Chinese population","volume":"17","author":"Lee","year":"2018","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jceh.2026.103631_bib110","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200005113421901","article-title":"Prospective study of the association between sleep-disordered breathing and hypertension","volume":"342","author":"Peppard","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jceh.2026.103631_bib111","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s12072-022-10347-2","article-title":"Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity","volume":"16","author":"Fu","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2026.103631_bib112","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.rmed.2015.02.010","article-title":"Relationship between energy expenditure, physical activity and weight loss during CPAP treatment in Obese OSA subjects","volume":"109","author":"Bamberga","year":"2015","journal-title":"Respir Med"},{"key":"10.1016\/j.jceh.2026.103631_bib113","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdi.12823","article-title":"Sleep apnea and type 2 diabetes","volume":"9","author":"Muraki","year":"2018","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.jceh.2026.103631_bib114","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ijo.2013.139","article-title":"Sleep fragmentation promotes NADPH oxidase 2-mediated adipose tissue inflammation leading to insulin resistance in mice","volume":"38","author":"Zhang","year":"2014","journal-title":"Int J Obes"},{"key":"10.1016\/j.jceh.2026.103631_bib115","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.2337\/dc15-0137","article-title":"Sleep disturbances and glucose metabolism in older adults: the cardiovascular health study","volume":"38","author":"Strand","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jceh.2026.103631_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.108837","article-title":"Long-term intermittent hypoxia in mice induces inflammatory pathways implicated in sleep apnea and steatohepatitis in humans","volume":"27","author":"Gaucher","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.jceh.2026.103631_bib117","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbadis.2011.02.014","article-title":"PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation","volume":"1812","author":"Varga","year":"2011","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.jceh.2026.103631_bib118","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jhep.2020.09.037","article-title":"Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis","volume":"74","author":"Mohs","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.08.013","article-title":"The role of IFN in the development of NAFLD and NASH","volume":"124","author":"M\u00f8hlenberg","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.jceh.2026.103631_bib120","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01768","article-title":"Uncovering the mysteries of langerhans cells, inflammatory dendritic epidermal cells, and monocyte-derived langerhans cell-like cells in the epidermis","volume":"9","author":"Otsuka","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib122","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib123","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jceh.2026.103631_bib124","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jceh.2026.103631_bib125","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Investig"},{"key":"10.1016\/j.jceh.2026.103631_bib126","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib127","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib128","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study","volume":"70","author":"Van Der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib129","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01549","article-title":"The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis","volume":"9","author":"Albanesi","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: a mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib131","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.3389\/fimmu.2019.01807","article-title":"Psoriasis: obesity and fatty acids","volume":"10","author":"Kunz","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib132","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jid.2018.11.023","article-title":"A transethnic mendelian randomization study identifies causality of obesity on risk of psoriasis","volume":"139","author":"Ogawa","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jceh.2026.103631_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.711060","article-title":"Metabolic syndrome and psoriasis: mechanisms and future directions","volume":"12","author":"Hao","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jceh.2026.103631_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jceh.2026.103631_bib135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4254\/wjh.v7.i3.315","article-title":"Non-alcoholic fatty liver disease and psoriasis: so far, so near","volume":"7","author":"Ganzetti","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib136","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib137","doi-asserted-by":"crossref","DOI":"10.1002\/jgh3.13038","article-title":"Low thyroid function is associated with metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Wang","year":"2024","journal-title":"JGH Open"},{"key":"10.1016\/j.jceh.2026.103631_bib138","article-title":"Low testosterone is associated with steatosis in the male population with spinal cord injury","volume":"68","author":"Coelho","year":"2025","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26199594","article-title":"Sex hormones and metabolic dysfunction-associated steatotic liver disease","volume":"26","author":"Weiskirchen","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jceh.2026.103631_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105445","article-title":"Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease","volume":"194","author":"Salva-Pastor","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.jceh.2026.103631_bib141","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ijo.2017.116","article-title":"High-free androgen index is associated with increased risk of non-alcoholic fatty liver disease in women with polycystic ovary syndrome, independent of obesity and insulin resistance","volume":"41","author":"Cai","year":"2017","journal-title":"Int J Obes"},{"key":"10.1016\/j.jceh.2026.103631_bib142","doi-asserted-by":"crossref","DOI":"10.1186\/s12978-018-0519-2","article-title":"A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis","volume":"15","author":"Wu","year":"2018","journal-title":"Reprod Health"},{"key":"10.1016\/j.jceh.2026.103631_bib143","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1515\/jpem-2022-0527","article-title":"Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight\/obese youth with polycystic ovary syndrome","volume":"36","author":"Patel-Sanchez","year":"2023","journal-title":"Journal of Pediatric Endocrinology and Metabolism"},{"key":"10.1016\/j.jceh.2026.103631_bib144","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1210\/clinem\/dgab658","article-title":"Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome","volume":"107","author":"Falzarano","year":"2022","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.jceh.2026.103631_bib145","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1210\/clinem\/dgaa753","article-title":"Adolescent nonalcoholic fatty liver disease and type 2 diabetes in young adulthood","volume":"106","author":"Bardugo","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jceh.2026.103631_bib146","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-11-133","article-title":"Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS)","volume":"11","author":"Baranova","year":"2013","journal-title":"J Transl Med"},{"key":"10.1016\/j.jceh.2026.103631_bib147","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8162421","article-title":"The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications","volume":"2017","author":"Alisi","year":"2017","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.jceh.2026.103631_bib148","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1042\/cs1020151","article-title":"Sex steroids and insulin resistance","volume":"102","author":"Livingstone","year":"2002","journal-title":"Clin Sci"},{"key":"10.1016\/j.jceh.2026.103631_bib149","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.1210\/en.2006-0879","article-title":"Regulation of adenosine 5\u2032,monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen-deficient state","volume":"147","author":"McInnes","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.jceh.2026.103631_bib150","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"Vos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jceh.2026.103631_bib151","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/thx.2009.131078","article-title":"Burden of comorbidity in individuals with asthma","volume":"65","author":"Gershon","year":"2010","journal-title":"Thorax"},{"key":"10.1016\/j.jceh.2026.103631_bib152","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1001\/archinte.159.21.2582","article-title":"Prospective study of body mass index, weight change, and risk of adult-onset asthma in women","volume":"159","author":"Camargo","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jceh.2026.103631_bib153","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/02770900802660931","article-title":"Asthma-like symptoms are increased in the metabolic syndrome","volume":"46","author":"Lee","year":"2009","journal-title":"J Asthma"},{"key":"10.1016\/j.jceh.2026.103631_bib154","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1183\/09031936.00046013","article-title":"Metabolic syndrome and incidence of asthma in adults: the HUNT study","volume":"42","author":"Brumpton","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jceh.2026.103631_bib155","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of biomarkers to identify phenotypes and endotypes of severe asthma","volume":"121","author":"Carr","year":"2018","journal-title":"Annals of Allergy, Asthma and Immunology"},{"key":"10.1016\/j.jceh.2026.103631_bib156","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1165\/rcmb.2016-0019PS","article-title":"Physiological mechanisms of airway hyperresponsiveness in obese asthma","volume":"54","author":"Bates","year":"2016","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jceh.2026.103631_bib157","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/diabetes.49.8.1374","article-title":"Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity","volume":"49","author":"Alessi","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.jceh.2026.103631_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100016","article-title":"TGF-\u03b2: the missing link in obesity-associated airway diseases?","volume":"2","author":"Woo","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.jceh.2026.103631_bib159","doi-asserted-by":"crossref","DOI":"10.3390\/cells8070685","article-title":"Advanced molecular knowledge of therapeutic drugs and natural products focusing on inflammatory cytokines in asthma","volume":"8","author":"Lin","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.jceh.2026.103631_bib160","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thoraxjnl-2020-215986","article-title":"Neutrophils in asthma: the good, the bad and the bacteria","volume":"76","author":"Crisford","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.jceh.2026.103631_bib161","article-title":"Association between nonalcoholic fatty liver disease and bone mineral density: mendelian randomization and mediation analysis","volume":"22","author":"Zheng","year":"2024","journal-title":"Bone Rep"},{"key":"10.1016\/j.jceh.2026.103631_bib162","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/jbmr.4862","article-title":"Nonalcoholic fatty liver disease is associated with decreased bone mineral density in adults: a systematic review and meta-analysis","volume":"38","author":"Su","year":"2023","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jceh.2026.103631_bib163","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.28376","article-title":"Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008-2011)","volume":"63","author":"Lee","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2026.103631_bib164","doi-asserted-by":"crossref","first-page":"326","DOI":"10.4254\/wjh.v9.i6.326","article-title":"Sarcopenia and non-alcoholic fatty liver disease: is there a relationship? A systematic review","volume":"9","author":"Tovo","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.maturitas.2020.05.012","article-title":"A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia","volume":"140","author":"Kirk","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.jceh.2026.103631_bib166","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/gutjnl-2021-324191","article-title":"Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies","volume":"71","author":"Mantovani","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jceh.2026.103631_bib167","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41575-018-0053-2","article-title":"Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms","volume":"15","author":"Ulrich","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib168","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2026.103631_bib169","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejca.2022.06.051","article-title":"Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"173","author":"Thomas","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jceh.2026.103631_bib170","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jceh.2026.103631_bib171","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i13.102563","article-title":"Helicobacter pylori infection is linked to metabolic dysfunction and associated steatotic liver disease: a large cross-sectional study","volume":"31","author":"Ye","year":"2025","journal-title":"World J Gastroenterol"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688326001635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T19:20:25Z","timestamp":1786562425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688326001635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":171,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0973688326001635"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103631","relation":{},"ISSN":["0973-6883"],"issn-type":[{"value":"0973-6883","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reframing MASLD: A Hepatic Condition With Systemic Clinical Impact","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2026.103631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103631"}}